Clinical impact of ceruloplasmin levels at ANCA-associated vasculitis diagnosis.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2024
Historique:
received: 02 04 2024
accepted: 23 09 2024
medline: 10 10 2024
pubmed: 10 10 2024
entrez: 10 10 2024
Statut: epublish

Résumé

Ceruloplasmin is an inhibitor of myeloperoxidase (MPO) activity that plays an important role in the pathophysiology of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). This study aimed to evaluate the prognostic impact of serum level of ceruloplasmin at diagnosis in patients with anti-MPO antibody-positive AAV. This retrospective monocentric study in Caen University Hospital involved all consecutive adult anti-MPO antibody-positive patients with microscopic polyangiitis or granulomatosis with polyangiitis, diagnosed between January 2010 and January 2022 with available serum sample at inclusion. Patients outcomes were analyzed from two subgroups constituted according to the median serum level of ceruloplasmin. The same analyses were then performed in anti-proteinase 3 (PR3) antibody-positive patients. Within the 92 patients analyzed, 50 patients had anti-MPO antibodies with a median ceruloplasmin level of 0.44 [quartiles 1-3, 0.40-0.49] g/L and a median Birmingham Vasculitis Activity Score of 19 [14-22]. After a median follow-up period of 40 [22-86] months, 13 (26%) patients had died: 10 (40%) in the low ceruloplasmin group and 3 (12%) in the high ceruloplasmin group (p = 0.03), with a significantly worse survival rate in the low ceruloplasmin group (p = 0.021). No significant differences in relapse rate or renal failure was observed between the two groups. The same analyses performed in the group of AAV patients with anti-PR3 antibody did not show any differences. In anti-MPO AAV patients, serum level of ceruloplasmin at diagnosis seems to be associated with a significant impact on survival.

Identifiants

pubmed: 39388433
doi: 10.1371/journal.pone.0311678
pii: PONE-D-24-07849
doi:

Substances chimiques

Ceruloplasmin EC 1.16.3.1
Peroxidase EC 1.11.1.7
Antibodies, Antineutrophil Cytoplasmic 0
Myeloblastin EC 3.4.21.76

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0311678

Informations de copyright

Copyright: © 2024 Camboulive et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Auteurs

Louis Camboulive (L)

Department of Internal Medicine, CHU de Caen Normandie, Caen, France.

Frédérique Grandhomme (F)

Laboratoire de Biochimie, CHU de Caen Normandie, Caen, France.

Nicolas Martin Silva (N)

Department of Internal Medicine, CHU de Caen Normandie, Caen, France.

Kathy Khoy (K)

Laboratoire d'Immunologie et d'Histocompatibilité, CHU de Caen Normandie, Caen, France.

Delphine Mariotte (D)

Laboratoire d'Immunologie et d'Histocompatibilité, CHU de Caen Normandie, Caen, France.

Thierry Lobbedez (T)

Department of Nephrology, CHU de Caen Normandie, Caen, France.

Anaël Dumont (A)

Department of Internal Medicine, CHU de Caen Normandie, Caen, France.

Alexandre Nguyen (A)

Department of Internal Medicine, CHU de Caen Normandie, Caen, France.

Hubert de Boysson (H)

Department of Internal Medicine, CHU de Caen Normandie, Caen, France.
Normandie Univ, UNICAEN, UR4650 PSIR, CHU de Caen Normandie, Caen, France.

Achille Aouba (A)

Department of Internal Medicine, CHU de Caen Normandie, Caen, France.

Samuel Deshayes (S)

Department of Internal Medicine, CHU de Caen Normandie, Caen, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH